FindTrial
Sign In

Fluorine [18F] betabene-based PET imaging: a clinical study for diagnosis and assessment of cognitive severity in patients with AD

Fluorine [18F] betabene-based PET imaging: a clinical study for diagnosis and assessment of cognitive severity in patients with AD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094692
Enrollment
Unknown
Registered
2024-12-26
Start date
2024-12-30
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Study Group:PET scintigraphy scan of fluoro[18F]betabenzene

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Participate in the study voluntarily and sign the informed consent form. 2.Age >= 18 years; 3.Patients diagnosed with MCI or AD by the 2023 NIA-AA Clinical Diagnostic Criteria for Alzheimer's Disease.

Exclusion criteria

Exclusion criteria: 1.Inability to comply with drug injections and PET scans, e.g., claustrophobic patients; 2.Inability to cooperate to complete MMSE and CDR scales; 3.History of organic brain disease.

Design outcomes

Primary

MeasureTime frame
Correlation between different patients's Aß deposition (Centiloid) and Common Dementia Scores (MMSE, CDR);—

Secondary

MeasureTime frame
Assessment of the adverse events;—

Countries

China

Contacts

Public ContactYing Wang

Fifth Affiliated Hospital, Sun Yat-Sen University

wangy9@mail.sysu.edu.cn+86 756 2528745

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026